Navigation Links
NIH-supported scientists demonstrate very early formation of SIV reservoir
Date:7/21/2014

WHAT:

Scientists have generally believed that HIV and its monkey equivalent, SIV, gain a permanent foothold in the body very early after infection, making it difficult to completely eliminate the virus even after antiretroviral therapy has controlled it. Now NIH-supported researchers report that SIV can become entrenched in tissues fewer than 3 days after infection, before the virus is detectable in blood plasma (the liquid part) or blood cells.

Led by Dan H. Barouch, M.D., Ph.D., of Beth Israel Deaconess Medical Center and the Ragon Institute, in collaboration with the U.S. Military HIV Research Program, the scientists infected 20 monkeys with a high dose of SIV and divided them into five groups. Four groups received triple-drug antiretroviral therapy for 6 months starting at 3, 7, 10 or 14 days after infection. The fifth group was not treated. The scientists tested the monkeys for SIV in their blood and tissues and for anti-SIV immune responses, and confirmed that the drug regimen fully suppressed viral replication in all the treated animals.

During treatment, testing detected immune responses to SIV in the blood of all monkeys except those that started treatment 3 days post infection. SIV DNA was detectable in cells of the gut and lymph nodes in all of the monkeys, and in blood cells of all but the day 3-treated monkeys.

After 6 months, the scientists halted treatment and the virus again became detectable in the blood of all the monkeys.

Together, these findings indicate that starting therapy for SIV 3 days post infection blunted the development of virus in blood but did not prevent it from establishing a permanent reservoir in tissues, including cells of the gut and lymph nodes. These data show that an irreversible viral reservoir is established very early following SIV infection in this animal model, and that early antiretroviral therapy therefore has a limited effect on the SIV reservoir in this model.


'/>"/>

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Toddler functionally cured of HIV infection, NIH-supported investigators report
2. NIH-supported researchers identify new class of malaria compounds
3. Scientists solving the mystery of human consciousness
4. Scientists uncover multiple faces of deadly breast cancer
5. Scientists identify major source of cells defense against oxidative stress
6. Scientists tailor cell surface targeting system to hit organelle ZIP codes
7. Scientists rewrite rulebook on breast cancer in landmark global study
8. Warwick scientists uncover how checkpoint proteins bind chromosomes
9. NIH scientists link quickly spreading gene to Asian MRSA epidemic
10. Joslin scientists identify important mechanism that affects the aging process
11. Scripps Research scientists show how memory B cells stay in class to fight different infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Ore. (PRWEB) , ... February 11, 2016 , ... ... Medicaid coverage results in significantly higher rates of several common cancer screenings, especially ... resulting in better outcomes and survival rates. , The study,“What Does Medicaid ...
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... PA (PRWEB) , ... February 10, 2016 , ... As ... offer two webinars in February 2016. Each webinar features a dynamic expert and ... to benefit their athletes, patients and facilities. Both events are free to attend, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Emergency rooms ... harder to find. Unfortunately, this can leave patients with dental emergencies at risk of ... is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... San Diego, will bring together more than 200 of the country’s top healthcare ... the future. , “The true benefit of the Forum is the provider-centric perspective, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
Breaking Medicine Technology: